Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP grew its holdings in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 8.0% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,372,499 shares of the company's stock after buying an additional 250,000 shares during the period. Repare Therapeutics accounts for approximately 3.1% of Blue Owl Capital Holdings LP's portfolio, making the stock its 10th largest position. Blue Owl Capital Holdings LP owned about 7.94% of Repare Therapeutics worth $11,129,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. XTX Topco Ltd acquired a new position in Repare Therapeutics in the 2nd quarter valued at about $110,000. Opaleye Management Inc. acquired a new position in shares of Repare Therapeutics in the first quarter valued at approximately $318,000. Marshall Wace LLP purchased a new stake in shares of Repare Therapeutics during the second quarter worth approximately $273,000. Bank of Montreal Can lifted its holdings in shares of Repare Therapeutics by 5.4% during the second quarter. Bank of Montreal Can now owns 110,935 shares of the company's stock worth $366,000 after purchasing an additional 5,673 shares during the period. Finally, Acadian Asset Management LLC grew its position in Repare Therapeutics by 53.5% in the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company's stock valued at $625,000 after buying an additional 46,648 shares during the last quarter. Institutional investors and hedge funds own 85.09% of the company's stock.

Repare Therapeutics Stock Performance

NASDAQ:RPTX traded down $0.06 during trading hours on Friday, hitting $3.44. The company's stock had a trading volume of 54,706 shares, compared to its average volume of 99,953. The company has a market capitalization of $146.03 million, a PE ratio of -3.13 and a beta of 0.71. Repare Therapeutics Inc. has a 52-week low of $2.71 and a 52-week high of $12.72. The business's 50-day moving average is $3.22 and its two-hundred day moving average is $3.58.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.03. The firm had revenue of $1.07 million during the quarter, compared to analysts' expectations of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. As a group, analysts predict that Repare Therapeutics Inc. will post -2.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on RPTX. Lifesci Capital upgraded shares of Repare Therapeutics to a "strong-buy" rating in a research note on Monday, July 29th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research report on Monday, September 23rd.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.